Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (11-20 of 303) with videos related to

Pageof 31
Sort By:
Medical Oncology (Northwood, London, England)|February 5, 2013
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single instituteBoram Han, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2016
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" DecisionMyung-Ju Ahn, Jong-Mu Sun, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2013
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancerYoung Saing Kim, Jong-Mu Sun, Jin Seok Ahn, et al.
Plos One|June 1, 2013
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancerJong-Mu Sun, Deok Won Hwang, Jin Seok Ahn, et al.
Expert Opinion on Pharmacotherapy|January 25, 2017
Osimertinib for the treatment of non-small cell lung cancerJong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2013
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitorsJong-Mu Sun, Myung-Ju Ahn, Yoon-La Choi, et al.
Japanese Journal of Clinical Oncology|November 13, 2015
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapySung Hee Lim, Su Jin Lee, Myung-Ju Ahn, et al.
Expert Opinion on Drug Safety|March 9, 2017
EGFR TKI combination with immunotherapy in non-small cell lung cancerMyung-Ju Ahn, Jong-Mu Sun, Se-Hoon Lee, et al.
Chemotherapy|December 5, 2014
Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal CancerHyun Ae Jung, Jong-Mu Sun, Se Hoon Park, et al.
Journal of Thoracic Disease|August 18, 2020
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?Jiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Pageof 31

Showing results (11-20 of 303) with videos related to

Sort By:
Pageof 31
Medical Oncology (Northwood, London, England)|February 5, 2013
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single instituteBoram Han, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2016
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" DecisionMyung-Ju Ahn, Jong-Mu Sun, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2013
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancerYoung Saing Kim, Jong-Mu Sun, Jin Seok Ahn, et al.
Plos One|June 1, 2013
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancerJong-Mu Sun, Deok Won Hwang, Jin Seok Ahn, et al.
Expert Opinion on Pharmacotherapy|January 25, 2017
Osimertinib for the treatment of non-small cell lung cancerJong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2013
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitorsJong-Mu Sun, Myung-Ju Ahn, Yoon-La Choi, et al.
Japanese Journal of Clinical Oncology|November 13, 2015
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapySung Hee Lim, Su Jin Lee, Myung-Ju Ahn, et al.
Expert Opinion on Drug Safety|March 9, 2017
EGFR TKI combination with immunotherapy in non-small cell lung cancerMyung-Ju Ahn, Jong-Mu Sun, Se-Hoon Lee, et al.
Chemotherapy|December 5, 2014
Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal CancerHyun Ae Jung, Jong-Mu Sun, Se Hoon Park, et al.
Journal of Thoracic Disease|August 18, 2020
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?Jiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Pageof 31